Aktienanalyse zu Dbv Technologies SA (DBVT)DBVTDbv Technologies SA

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Currently, DBV Technologies is trading at $9.80, significantly below the analyst price targets which range from $40 to $55, indicating potential upside. However, the stock has a low RSI of 24.475, suggesting it is oversold, but the recent 5-day change of -7.11% and year-to-date change of -48.56% indicate ongoing downward pressure. The main risk is the negative net income reported, which was -$50.4 million in Q2 2026, raising concerns about profitability.

9 analysts cover DBVT: 8 rate it Buy, 1 Hold and 0 Sell. The average price target is 46.40.